Evaluation of a Pharmacist-Led Diabetes Collaborative Drug Therapy Management Service

2021 ◽  
pp. 089719002110086
Author(s):  
Elizabeth M. Bald ◽  
Chad Triplett ◽  
Randi Beranek ◽  
Korey Kennelty

Objective: To evaluate the pharmacist-led diabetes collaborative drug therapy management services in a family medicine and internal medicine clinic. Design: Mixed methods of evaluation based on the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework. Results: Reach: 71.3% of patients who were independently consulted (n = 184/258) and 1.6% (n = 11/680) of patients who triggered a best practice advisory (BPA) were enrolled. Effectiveness: 27.7% of patients (n = 54/195) enrolled were lost to follow-up. Adoption: 55% of eligible providers (n = 77/140) have placed a consult. Implementation: Providers independently choose to refer patients and are also prompted to place consults by a BPA that triggers for patients with an HbA1c ≥ 9%. Common reasons providers did not place a consult include: alignment with workflow, patient refusal, and patients followed by other services. Regarding patient perceptions, patients valued the service. Patients reported increased accountability with disease state maintenance and increased self-efficacy. Regarding how to improve the service, patients wanted more information on expectations before engaging with the pharmacist. Patients suggested to replicate this service for pain, cancer, and blood pressure management. Maintenance: 96.7% of providers (n = 30/31) reported they were very likely/likely to place a consult in the future and 60% of providers (n = 18/30) reported they were very likely/likely to place a consult when prompted by the BPA. Conclusion: These results can be utilized to make improvements to the pharmacist-led diabetes collaborative drug therapy management service to ensure sustainability. This study also provides lessons learned and strategies for future adoption, implementation, and maintenance of similar services for other disease states.

2012 ◽  
Vol 69 (22) ◽  
pp. 1993-1998 ◽  
Author(s):  
Tanna Cooper ◽  
Carol L. White ◽  
David Taber ◽  
Walter E. Uber ◽  
Heather Kokko ◽  
...  

2018 ◽  
Vol 9 (1) ◽  
pp. 6
Author(s):  
Maria Sorbera ◽  
Cathleen Mathew ◽  
Shannon Christy Ramdeen

 Purpose: Being the leading cause of liver disease and hepatocellular carcinoma, the hepatitis C virus (HCV) has become a growing public health threat within the United States. Of those individuals infected with human immunodeficiency virus (HIV), approximately 25% are co- infected with HCV. Establishment of a hepatitis C collaborative drug therapy management (CDTM) service can expand the role of pharmacists in an interdisciplinary team improving health outcomes for an underserved HIV/HCV co-infected patient population. Summary: In 2016, physicians and pharmacists identified a need to establish Hepatitis C pharmacy services in an HIV clinic. Through the recent establishment of CDTM and implementation of pharmacy services, pharmacists are now given the autonomy to manage patients co-infected with HIV/HCV. It is believed that the addition of a clinical pharmacist to an interdisciplinary team will lead to improved SVR rates, adherence, and clinic revenue, as well as decreased ADRs and drug-drug interactions among co-infected patients. Conclusion: Implementation of HCV pharmacy services directed towards HIV/HCV co- infection is an essential patient-centered strategy addressing complex medication-related problems in an attempt to achieve optimal therapeutic outcomes. A single-centered, prospective study to evaluate HCV pharmacy services at the Treatment for Life Center clinic is currently ongoing. Conflict of Interest We declare no conflicts of interest or financial interests that the authors or members of their immediate families have in any product or service discussed in the manuscript, including grants (pending or received), employment, gifts, stock holdings or options, honoraria, consultancies, expert testimony, patents and royalties   Type: Clinical Experience


2016 ◽  
Vol 73 (18) ◽  
pp. 1388-1390 ◽  
Author(s):  
Jennifer Andres ◽  
Charles Ruchalski ◽  
Paul Katz ◽  
Guillermo Linares

Author(s):  
American College of Clinical Pharmacy ◽  
Raymond W. Hammond ◽  
Amy H. Schwartz ◽  
Marla J. Campbell ◽  
Tami L. Remington ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document